Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TOP1 | P11387 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2321053 | 0.80 | CYP3A4 (0.47) | ALDH1A1CA2CYP3A4TSHRTDP1 | |
| SCHEMBL28194456 | 0.78 | ALDH1A1 (0.48) | ALDH1A1CA2CYP3A4TSHRTDP1 | |
| SCHEMBL21144801 | 0.78 | ALDH1A1 (0.48) | ALDH1A1CA2CYP3A4TSHRTDP1 | |
| SCHEMBL30515755 | 0.78 | ALDH1A1 (0.40) | ALDH1A1LMNATOP1 | |
| SCHEMBL23234144 | 0.77 | EPHX2 (0.41) | ALDH1A1LMNA | |
| SCHEMBL198354 | 0.77 | EPHX2 (0.41) | ALDH1A1LMNA | |
| SCHEMBL61278 | 0.77 | EPHX2 (0.41) | ALDH1A1LMNA | |
| SCHEMBL23016820 | 0.77 | EPHX2 (0.41) | ALDH1A1LMNA | |
| SCHEMBL788641 | 0.77 | EPHX2 (0.41) | ALDH1A1LMNA | |
| SCHEMBL15977917 | 0.77 | EPHX2 (0.41) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020071820-A1 | Protecting body against the effects of pollution; preferably an aqueous dispersion of 3,7,11,15-tetramethyl-1,2,3-hexadecanetriol, phytanetriol, N-2-alkoxycarbonyl derivatives of N-methylglucamine or monoglycerides | L'OREAL (FR) | 2002-06-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020071820-A1 | Protecting body against the effects of pollution; preferably an aqueous dispersion of 3,7,11,15-tetramethyl-1,2,3-hexadecanetriol, phytanetriol, N-2-alkoxycarbonyl derivatives of N-methylglucamine or monoglycerides | KRT18, PLIN3, TK1 | ALDH1A1 3359/4885CA2 2894/4885CYP3A4 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.